Cardiovascular outcomes and safety of SGLT2 inhibitors in rheumatic diseases: a systematic review of evidence predominantly from systemic lupus erythematosus and systemic sclerosis
Cardiovascular outcomes and safety of SGLT2 inhibitors in rheumatic diseases: a systematic review of evidence predominantly from systemic lupus erythematosus and systemic sclerosis. // Seminars in Arthritis and Rheumatism. – URL: https://www.sciencedirect.com/science/article/pii/S0049017226001800?dgcid=rss_sd_all
Cardiovascular outcomes and safety of SGLT2 inhibitors in rheumatic diseases: a systematic review of evidence predominantly from systemic lupus erythematosus and systemic sclerosis. Seminars in Arthritis and Rheumatism. https://www.sciencedirect.com/science/article/pii/S0049017226001800?dgcid=rss_sd_all
“Cardiovascular outcomes and safety of SGLT2 inhibitors in rheumatic diseases: a systematic review of evidence predominantly from systemic lupus erythematosus and systemic sclerosis.” Seminars in Arthritis and Rheumatism.
@article{article65518,
title = {Cardiovascular outcomes and safety of SGLT2 inhibitors in rheumatic diseases: a systematic review of evidence predominantly from systemic lupus erythematosus and systemic sclerosis},
journal = {Seminars in Arthritis and Rheumatism},
url = {https://www.sciencedirect.com/science/article/pii/S0049017226001800?dgcid=rss_sd_all}
}